Blocking VRK2 suppresses pulmonary adenocarcinoma progression via ERK1/2/AKT signal pathway by targeting miR-145-5p
Y. Mu, W.-J. Liu, L.-Y. Bie, X.-Q. Mu, Y.-Q. Zhao Department of Oncology, Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital, Zhengzhou, Henan Province, China.
The article “Blocking VRK2 suppresses pulmonary adenocarcinoma progression via ERK1/2/AKT signal pathway by targeting miR-145-5p, by Y. Mu, W.-J. Liu, L.-Y. Bie, X.-Q. Mu, Y.-Q. Zhao, published in Eur Rev Med Pharmacol Sci 2021; 25 (1): 145-153–DOI: 10.26355/eurrev_202101_24378–PMID: 33506902” has been withdrawn from the authors since the design of the manuscript was not rigorous enough (there were some flaws in some experiments).
The authors explain that they will perform further experiments.
The Publisher apologizes for any inconvenience this may cause.
https://www.staging.europeanreview.org/article/24378
Free PDF Download
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License
To cite this article
Y. Mu, W.-J. Liu, L.-Y. Bie, X.-Q. Mu, Y.-Q. Zhao
Blocking VRK2 suppresses pulmonary adenocarcinoma progression via ERK1/2/AKT signal pathway by targeting miR-145-5p
Eur Rev Med Pharmacol Sci
Year: 2021
Vol. 25 - N. 11
Pages: 3933-3933
DOI: 10.26355/eurrev_202106_26026